{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:37:32Z","timestamp":1790505452238,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["239837"],"award-info":[{"award-number":["239837"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["144345-2014"],"award-info":[{"award-number":["144345-2014"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>p53 protein isoform expression has been found to correlate with prognosis and chemotherapy response in acute myeloid leukemia (AML). We aimed to investigate how p53 protein isoforms are modulated during epigenetic differentiation therapy in AML, and if p53 isoform expression could be a potential biomarker for predicting a response to this treatment. p53 full-length (FL), p53\u03b2 and p53\u03b3 protein isoforms were analyzed by 1D and 2D gel immunoblots in AML cell lines, primary AML cells from untreated patients and AML cells from patients before and after treatment with valproic acid (VPA), all-trans retinoic acid (ATRA) and theophylline. Furthermore, global gene expression profiling analysis was performed on samples from the clinical protocol. Correlation analyses were performed between p53 protein isoform expression and in vitro VPA sensitivity and FAB (French\u2013American\u2013British) class in primary AML cells. The results show downregulation of p53\u03b2\/\u03b3 and upregulation of p53FL in AML cell lines treated with VPA, and in some of the patients treated with differentiation therapy. p53FL positively correlated with in vitro VPA sensitivity and the FAB class of AML, while p53\u03b2\/\u03b3 isoforms negatively correlated with the same. Our results indicate that p53 protein isoforms are modulated by and may predict sensitivity to differentiation therapy in AML.<\/jats:p>","DOI":"10.3390\/cells10040833","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T11:31:59Z","timestamp":1617795119000},"page":"833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy"],"prefix":"10.3390","volume":"10","author":[{"given":"Ingvild","family":"Haaland","sequence":"first","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun M.","family":"Hjelle","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-8411","authenticated-orcid":false,"given":"H\u00e5kon","family":"Reikvam","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"},{"name":"Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Sulen","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Ryningen","sequence":"additional","affiliation":[{"name":"Chemistry and Biomedical Laboratory Sciences, Department of Safety, Faculty of Engineering and Natural Sciences, Western Norway University of Applied Sciences, 5063 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-4625","authenticated-orcid":false,"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"},{"name":"Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-9704","authenticated-orcid":false,"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"},{"name":"Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"},{"name":"Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Anbarasan, T., and Bourdon, J.-C. (2019). The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246257"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/carcin\/bgaa071","article-title":"Targeting cellular senescence in cancer and aging: Roles of p53 and its isoforms","volume":"41","author":"Beck","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14737159.2019.1563484","article-title":"What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?","volume":"19","author":"Hayman","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/OTT.S53876","article-title":"Uncovering the role of p53 splice variants in human malignancy: A clinical perspective","volume":"7","author":"Bourdon","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1101\/gad.1339905","article-title":"p53 isoforms can regulate p53 transcriptional activity","volume":"19","author":"Bourdon","year":"2005","journal-title":"Genes Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.cdd.4401914","article-title":"p53\/p63\/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress","volume":"13","author":"Lane","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/cdd.2011.120","article-title":"Biological functions of p53 isoforms through evolution: Lessons from animal and cellular models","volume":"18","author":"Marcel","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"a026039","DOI":"10.1101\/cshperspect.a026039","article-title":"p53 Isoforms: Key Regulators of the Cell Fate Decision","volume":"6","author":"Joruiz","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.2147\/CMAR.S263559","article-title":"\u0394133p53\/FLp53 Predicts Poor Clinical Outcome in Esophageal Squamous Cell Carcinoma","volume":"12","author":"Tu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1861-1","article-title":"The \u0394133p53\u03b2 isoform promotes an immunosuppressive environment leading to aggressive prostate cancer","volume":"10","author":"Kazantseva","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/bjc.2011.433","article-title":"\u0394133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer","volume":"105","author":"Hofstetter","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-41706-z","article-title":"Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers","volume":"9","author":"Bischof","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/carcin\/bgy001","article-title":"p53\u03b2: A new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up","volume":"39","author":"Zhang","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_14","first-page":"586","article-title":"The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome","volume":"35","author":"Morten","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr2811","article-title":"p53 mutant breast cancer patients expressing p53\u03b3 have as good a prognosis as wild-type p53 breast cancer patients","volume":"13","author":"Bourdon","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_16","first-page":"1533","article-title":"Correlation analysis of p53 protein isoforms with NPM1\/FLT3 mutations and therapy response in acute myeloid leukemia","volume":"31","author":"Hjelle","year":"2011","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: Projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/modpathol.2014.153","article-title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome","volume":"28","author":"Cleven","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1158\/1078-0432.CCR-05-1970","article-title":"A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia","volume":"12","author":"Anensen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3324\/haematol.2020.262121","article-title":"Differentiation therapy of myeloid leukemia: Four decades of development","volume":"106","author":"Madan","year":"2020","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and Retinoic Acid in Combination with Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 \u00d7 2, Phase II Trial","volume":"38","author":"Grishina","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"123","author":"Tassara","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Raffoux","year":"2010","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/15258160260090933","article-title":"Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses","volume":"11","author":"Gjertsen","year":"2002","journal-title":"J. Hematother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chrisanthar, R., Knappskog, S., L\u00f8kkevik, E., Anker, G., \u00d8stenstad, B., Lundgren, S., Berge, E.O., Risberg, T., Mjaaland, I., and M\u00e6hle, L. (2008). CHEK2 Mutations Affecting Kinase Activity Together with Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003062"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia","volume":"26","author":"McCormack","year":"2011","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","article-title":"A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid","volume":"33","author":"Ryningen","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Reikvam, H., Hovland, R., Forthun, R.B., Erdal, S., Gjertsen, B.T., Fredly, H., and Bruserud, \u00d8. (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia\u2014Identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3620-y"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Van Belle, W., Anensen, N., Haaland, I., Bruserud, \u00d8., H\u00f8gda, K.-A., and Gjertsen, B.T. (2006). Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinform., 7.","DOI":"10.1186\/1471-2105-7-198"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/MCB.19.1.12","article-title":"p53-Mediated Regulation of Proliferating Cell Nuclear Antigen Expression in Cells Exposed to Ionizing Radiation","volume":"19","author":"Xu","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1074\/jbc.RA118.005167","article-title":"Preferential digestion of PCNA-ubiquitin and p53-ubiquitin linkages by USP7 to remove polyubiquitin chains from substrates","volume":"294","author":"Masuda","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1074\/jbc.M108302200","article-title":"PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy","volume":"277","author":"Mayo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/0008-5472.CAN-05-1557","article-title":"PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner","volume":"66","author":"Tang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nature07443","article-title":"p53 and Pten control neural and glioma stem\/progenitor cell renewal and differentiation","volume":"455","author":"Zheng","year":"2008","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcancer.2013.12.006","article-title":"p53 orchestrates between normal differentiation and cancer","volume":"32","author":"Rivlin","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/cdd.2014.73","article-title":"Modulation of p53\u03b2 and p53\u03b3 expression by regulating the alternative splicing of TP53 gene modifies cellular response","volume":"21","author":"Marcel","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ncb1928","article-title":"p53 isoforms \u0394133p53 and p53\u03b2 are endogenous regulators of replicative cellular senescence","volume":"11","author":"Fujita","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Silden, E., Hjelle, S.M., Wergeland, L., Sulen, A., Andresen, V., Bourdon, J.-C., Micklem, D.R., McCormack, E., and Gjertsen, B.T. (2013). Expression of TP53 Isoforms p53\u03b2 or p53\u03b3 Enhances Chemosensitivity in TP53null Cell Lines. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056276"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc.2017.103","article-title":"Differentiation therapy revisited","volume":"18","year":"2018","journal-title":"Nat. Rev. Cancer"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/4\/833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:12:01Z","timestamp":1760364721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/4\/833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cells10040833"],"URL":"https:\/\/doi.org\/10.3390\/cells10040833","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}